Cuprina Secures Exclusive Rights to Southeast Asia’s First UNIDO/GEF- Demonstrated Medical Waste Recycling Technology
Cuprina Holdings (Nasdaq: CUPR) has secured exclusive licensing rights to Southeast Asia's first UNIDO/GEF-demonstrated medical waste recycling technology. The technology, licensed from Zhejiang Heliang Technology, uses advanced high-temperature steam treatment to sterilize and recycle medical waste into high-value resins, particularly focusing on plastic-based materials.
The license covers Singapore with expansion options to 10 additional Southeast Asian countries. The technology offers an environmentally friendly alternative to traditional incineration methods, supported by extensive regulatory approvals and ISO certifications (9001, 14001, 45001). Singapore's biohazardous medical waste increased from 4,400 tons in 2016 to 5,700 tons in 2020, growing approximately 5% annually.
The global medical waste management market is projected to grow from $34.06 billion in 2023 to $59.42 billion by 2030, with Asia-Pacific as the fastest-growing region.
Cuprina Holdings (Nasdaq: CUPR) ha acquisito i diritti di licenza esclusiva per la prima tecnologia di riciclaggio dei rifiuti medicali dimostrata da UNIDO/GEF nel Sud-est asiatico. La tecnologia, concessa in licenza da Zhejiang Heliang Technology, utilizza un avanzato trattamento a vapore ad alta temperatura per sterilizzare e trasformare i rifiuti medicali in resine ad alto valore, con particolare attenzione ai materiali plastici.
La licenza copre Singapore con opzioni di espansione verso altri 10 Paesi del Sud-est asiatico. La tecnologia rappresenta un'alternativa ecologica alla tradizionale incenerimento, supportata da ampie approvazioni regolatorie e certificazioni ISO (9001, 14001, 45001). I rifiuti medicali biologicamente pericolosi a Singapore sono aumentati da 4.400 tonnellate nel 2016 a 5.700 tonnellate nel 2020, con una crescita di circa il 5% annuo.
Il mercato globale della gestione dei rifiuti medicali è previsto crescere da 34,06 miliardi di dollari nel 2023 a 59,42 miliardi di dollari entro il 2030, con l'Asia-Pacifico come regione in più rapida espansione.
Cuprina Holdings (Nasdaq: CUPR) ha asegurado los derechos de licencia exclusivos para la primera tecnología de reciclaje de residuos médicos demostrada por UNIDO/GEF en el sudeste asiático. La tecnología, licenciada por Zhejiang Heliang Technology, utiliza un avanzado tratamiento con vapor a alta temperatura para esterilizar y reciclar residuos médicos en resinas de alto valor, con especial enfoque en materiales plásticos.
La licencia cubre Singapur con opciones de expansión a 10 países adicionales del sudeste asiático. La tecnología ofrece una alternativa ecológica a los métodos tradicionales de incineración, respaldada por amplias aprobaciones regulatorias y certificaciones ISO (9001, 14001, 45001). Los residuos médicos bio-peligrosos en Singapur aumentaron de 4.400 toneladas en 2016 a 5.700 toneladas en 2020, creciendo aproximadamente un 5% anual.
Se proyecta que el mercado global de gestión de residuos médicos crecerá de 34.060 millones de dólares en 2023 a 59.420 millones de dólares para 2030, siendo Asia-Pacífico la región de más rápido crecimiento.
Cuprina Holdings (Nasdaq: CUPR)는 동남아시아에서 UNIDO/GEF가 입증한 최초의 의료 폐기물 재활용 기술에 대한 독점 라이선스 권리를 확보했습니다. 해당 기술은 Zhejiang Heliang Technology로부터 라이선스되었으며, 고온 증기 처리를 통해 의료 폐기물을 멸균하고 특히 플라스틱 기반 재료를 고부가가치 수지로 재활용합니다.
라이선스는 싱가포르를 포함하며 동남아시아 10개국으로 확장 가능한 옵션을 제공합니다. 이 기술은 전통적 소각 방식에 대한 환경친화적 대안으로, 광범위한 규제 승인과 ISO 인증(9001, 14001, 45001)을 보유하고 있습니다. 싱가포르의 생물학적 위험 의료 폐기물은 2016년 4,400톤에서 2020년 5,700톤으로 증가했으며 연평균 약 5% 성장했습니다.
전 세계 의료 폐기물 관리 시장은 2023년 340.6억 달러에서 2030년 594.2억 달러로 성장할 것으로 전망되며, 아시아·태평양 지역이 가장 빠르게 성장하는 지역입니다.
Cuprina Holdings (Nasdaq: CUPR) a obtenu les droits de licence exclusifs sur la première technologie de recyclage des déchets médicaux démontrée par l'UNIDO/GEF en Asie du Sud-Est. La technologie, sous licence de Zhejiang Heliang Technology, utilise un procédé avancé de traitement à la vapeur haute température pour stériliser et recycler les déchets médicaux en résines à forte valeur ajoutée, en se concentrant particulièrement sur les matériaux plastiques.
La licence couvre Singapour avec des options d'expansion vers 10 pays supplémentaires d'Asie du Sud-Est. La technologie offre une alternative respectueuse de l'environnement aux méthodes traditionnelles d'incinération, soutenue par de nombreuses approbations réglementaires et des certifications ISO (9001, 14001, 45001). Les déchets médicaux biologiquement dangereux à Singapour sont passés de 4 400 tonnes en 2016 à 5 700 tonnes en 2020, soit une croissance d'environ 5 % par an.
Le marché mondial de la gestion des déchets médicaux devrait passer de 34,06 milliards de dollars en 2023 à 59,42 milliards de dollars d'ici 2030, l'Asie-Pacifique étant la région à la croissance la plus rapide.
Cuprina Holdings (Nasdaq: CUPR) hat exklusive Lizenzrechte an der ersten von UNIDO/GEF in Südostasien nachgewiesenen Technologie zur Wiederverwertung medizinischer Abfälle erworben. Die von Zhejiang Heliang Technology lizenzierte Technologie nutzt eine fortschrittliche Hochtemperatur-Dampfbehandlung, um medizinische Abfälle zu sterilisieren und insbesondere Kunststoffmaterialien in hochwertigere Harze umzuwandeln.
Die Lizenz deckt Singapur mit Expansionsoptionen auf weitere 10 Länder in Südostasien ab. Die Technologie bietet eine umweltfreundliche Alternative zu herkömmlichen Verbrennungsverfahren und wird durch umfangreiche behördliche Zulassungen und ISO-Zertifikate (9001, 14001, 45001) gestützt. Die biologisch gefährlichen medizinischen Abfälle in Singapur stiegen von 4.400 Tonnen im Jahr 2016 auf 5.700 Tonnen im Jahr 2020, bei einer jährlichen Wachstumsrate von etwa 5%.
Der globale Markt für das Management medizinischer Abfälle soll von 34,06 Milliarden USD im Jahr 2023 auf 59,42 Milliarden USD bis 2030 wachsen, wobei die Region Asien-Pazifik am schnellsten wächst.
- Exclusive licensing rights for an environmentally friendly medical waste recycling technology in Singapore
- Option to expand into 10 additional Southeast Asian countries
- Technology validated over two decades with ISO certifications and regulatory approvals
- Targeting fast-growing market projected to reach $59.42B by 2030
- Addresses growing medical waste problem in Singapore (5% annual growth)
- Still needs to obtain operating licenses in Singapore
- Requires construction of new facility with associated costs
- Integration with existing waste management framework pending
Insights
Cuprina's exclusive license for advanced medical waste recycling technology positions it strategically in Southeast Asia's growing $34B market with environmental advantages.
This technology acquisition represents a strategic pivot for Cuprina, diversifying beyond its core biomedical and biotechnology focus into the $34.06 billion medical waste management market. The exclusive license provides Cuprina immediate access to Singapore—with options for ten additional Southeast Asian countries—positioning it at the forefront of the region's 8% annual growth in this sector.
The technology's differentiation is significant. While conventional methods incinerate waste and create toxic emissions and landfill burdens, this system employs high-temperature steam sterilization that preserves plastic materials for recycling into high-value resins. This closed-loop approach addresses two critical challenges: Singapore's limited landfill capacity and growing medical waste volumes, which increased from 4,400 tons in 2016 to 5,700 tons in 2020—a
The technology's credibility stems from its two decades of development under UNIDO and GEF oversight, with ISO certifications in quality management, environmental management, and occupational health. This validation substantially reduces implementation risks and regulatory hurdles compared to untested technologies.
The market timing appears advantageous as Asian governments increasingly adopt stricter environmental standards. By establishing Singapore as the first deployment hub outside China, Cuprina gains first-mover advantage in the fastest-growing region for medical waste management globally. Revenue potential could be substantial as healthcare facilities seek compliant, sustainable alternatives to traditional disposal methods.
SINGAPORE, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it has secured exclusive licensing rights to Southeast Asia’s first medical waste recycling technology developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF), the major alliance supporting developing countries in achieving global environmental benefits.
The license, signed by Cuprina with China-based Zhejiang Heliang Technology Co., Ltd., covers Singapore and an option to expand into ten additional Southeast Asian countries.
As opposed to current medical waste technologies which incinerate waste and send its ash to landfills – a method that releases toxic emissions and strains Singapore’s already limited landfill capacity – the new technology uses advanced high-temperature steam treatment to sterilize and decontaminate medical waste, particularly plastic-based materials. Once clean, these materials are sorted and recycled into high-value resins and converted into sustainable raw materials that re-enter the economy.
The technology has gained validation over two decades via collaboration between Chinese authorities, UNIDO, and GEF, as well as via ISO certifications (9001, 14001, 45001) and extensive regulatory approvals.
Cuprina intends to apply for the operating licenses required in Singapore to construct a facility for the new technology, and is also engaging with the nation’s leading toxic waste disposal companies to integrate these processes seamlessly into the national waste management framework.
By establishing Singapore as the first hub for the technology outside of China, Cuprina aims to capture significant growth opportunities across Southeast Asia, where many governments are tightening environmental standards.
In Singapore, biohazardous medical waste increased from 4,400 tons in 2016 to 5,700 tons in 2020, an average annual increase of around
According to a recent study by Grand View Research, the global medical waste management market was valued at USD 34.06 billion in 2023 and is projected to reach USD 59.42 billion by 2030, growing at
“This isn’t just about new equipment—it’s about bringing in a globally validated technology that has been refined, certified, and proven over two decades,” said Cuprina CEO David Quek Yong Qi. “By securing exclusive rights for Southeast Asia, Cuprina expects to lead the transition from incineration and landfill toward a new model that protects public health, safeguards the environment, and creates long-term value for our shareholders.”
About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards.
For more information, please visit https://cuprina.com/
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com
FAQ
What exclusive rights did Cuprina (CUPR) secure for medical waste recycling?
How does Cuprina's new medical waste recycling technology work?
What is the market size for medical waste management that Cuprina (CUPR) is targeting?
How much medical waste does Singapore currently produce?
What regulatory approvals does Cuprina need for the medical waste technology?
